Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.73 |
| ▸ | HTR2A | P28223 | 5/20 | 0.73 |
| ▸ | HTR7 | P34969 | 4/20 | 0.73 |
| ▸ | HTR6 | P50406 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perospirone SCHEMBL6691734 | 1.00 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL30061058 | 1.00 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL29846330 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1155757 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28506465 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1651000 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1865565 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL5435087 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28054292 | 0.94 | HTR1A (0.89) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| SCHEMBL7283429 | 0.88 | HTR1A (0.79) | HTR1ALMNACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3358 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| US-20250333792-A1 | GENE PANEL FOR IDENTIFYING HYPO SEPSIS PHENOTYPE PATIENTS | UNIV FLORIDA (US) | 2025-10-30 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250235443-A1 | USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION | MINERVA NEUROSCIENCES, INC. | 2025-07-24 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| EP-1238676-B1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1404342-A1 | TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1353675-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2003066039-A1 | COMBINATION THERAPY FOR TREATMENT OF SCHIZOPHRENIA | ABBOTT LABORATORIES (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030109546-A1 | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | claimed |
| WO-2002087590-A1 | TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020156067-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| EP-1238676-A1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002053140-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-11 | — | — | WO | claimed |